trader score
+0.61
hit rate
65%
mean α
+0.27%
signals 14d
14
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 65% hit rate, +0.27% mean alpha, trader score +0.61. Their last-14d mentions, direction-adjusted, have moved +1.6% since posting (mean over 8 mentions with price data).
Recent signals14receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | · | @ManOnThePen | · | Warns that peptide marketing has outpaced oversight and that compounding-list inclusion is not approval. | · | tweet ↗ |
| 2026-10-15 | · | @ManOnThePen | · | Expects compounded-peptide access to slow RUO-brand growth only slightly without materially shrinking the market. | · | tweet ↗ |
| 2026-10-14 | · | @ManOnThePen | · | Reports a Zealand-Generate obesity-drug partnership worth up to $1.2B plus royalties and $30M upfront. | · | tweet ↗ |
| 2026-10-14 | NVO | @ManOnThePen | +0.35 | Reports lower-priced Korean obesity-drug competition and NVO seeking national insurance coverage for Wegovy. | +2.4% | tweet ↗ |
| 2026-10-14 | LLY | @ManOnThePen | -0.25 | Reports lower-priced Korean obesity-drug competition and NVO seeking national insurance coverage for Wegovy. | +5.4% | tweet ↗ |
| 2026-10-13 | LLY | @ManOnThePen | -0.35 | FDA again ruled retatrutide is a drug, while DOJ seeks delay or dismissal of Lilly's appeal. | +9.2% | tweet ↗ |
| 2026-10-08 | LLY | @ManOnThePen | +0.40 | Argues gray-market competitors face payment, FDA and litigation risks and Lilly will become more aggressive. | +8.9% | tweet ↗ |
| 2026-10-07 | · | @ManOnThePen | · | Supports moving oral GLP-1 drugs behind the pharmacy counter based on existing risky consumer behavior. | · | tweet ↗ |
| 2026-10-07 | LLY | @ManOnThePen | +0.50 | Argues tirzepatide's success can fund Lilly's expansion into new science and hard-to-treat diseases. | +7.1% | tweet ↗ |
| 2026-10-05 | CVS | @ManOnThePen | +0.10 | Reports negotiated and coupon-adjusted Zepbound cash pricing across insurers and pharmacy. | +7.4% | tweet ↗ |
| 2026-10-05 | CI | @ManOnThePen | +0.10 | Reports negotiated and coupon-adjusted Zepbound cash pricing across insurers and pharmacy. | +13.1% | tweet ↗ |
| 2026-10-05 | LLY | @ManOnThePen | -0.10 | Reports negotiated and coupon-adjusted Zepbound cash pricing across insurers and pharmacy. | +11.4% | tweet ↗ |
| 2026-10-05 | · | @ManOnThePen | · | Advocates making oral GLP-1 treatment available over the counter. | · | tweet ↗ |
| 2026-10-04 | · | @ManOnThePen | · | Advocates behind-the-counter access for oral GLP-1 medicines. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.